Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin’s Lymphoma-Reference-Cited by-同舟云学术

Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin’s Lymphoma

Published:2023-09-15 Issue: Volume:23 Page:
ISSN:1389-5575
Container-title:Mini-Reviews in Medicinal Chemistry
language:en
Short-container-title:MRMC

Author:

Liu Shuxian¹^ORCID,Xu Minghao¹^ORCID,Zhong Lei²,Tong Xiangmin³,Qian Suying⁴

Affiliation:

1. Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines，School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China

2. Tongxiang Hospital of Traditional Chinese Medicine, China

3. Zhejiang Provincial People's Hospital , Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China

4. Ningbo No. 2 Hospital, Department of Hematology and Oncology, Ningbo, China

Abstract

Abstract: Lymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), central nerve cell lymphoma, and follicular lymphoma. The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology,General Medicine